Using serum cystatin C as a biomarker for AKI could prove to be a valuable addition to diagnostic protocols, a study reports.

Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
In the phase 3 REGENCY trial, adding obinutuzumab to standard therapy for lupus nephritis led to better renal outcomes.
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Drs. Peter Richardson and George Wan of Mallinckrodt Pharmaceuticals discussed new data on terlipressin for HRS-AKI.
Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
The American Society of Nephrology (ASN) will create a Centers of Excellence in Home Dialysis pilot program.
Chris Klug, Timothy Caulfield, Borys Todurov, and Hongkui Deng will be keynote speakers at the World Transplant Congress.
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Researchers fitted a face mask with a breath sensor that may be able to detect the presence of chronic kidney disease.
This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD).
Advertisement
Expert Interviews
Conferences
Podcasts
This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD).
This Freely Filtered episode discusses REGENCY, examining the efficacy and safety of obinutuzumab in active lupus nephritis.
Listen to the discussion of Chapter 18 of Dr. Burton Rose's book, focused on metabolic alkalosis.
Freely Filtered returns with another episode for NephMadness, this time, covering the hemodialysis region.
Expert Columns
Ajay Singh talks dialytrauma—harmful effects of dialysis in patients with AKI moving from inpatient to outpatient care.
Sarah Tolson reviews how changes to reimbursement for phosphate binders have affected dialysis programs.
Ajay Singh discusses the state of rare kidney disease research.
Sarah Tolson highlights the concerns and challenges dialysis programs face under the 2025 ESRD PPS requirements.
Dr. Ajay Singh and others pay tribute to Dr. Barry Brenner, a leading nephrologist who passed away in August 2024.
Sarah Tolson shares what billing departments of dialysis programs need to know about the CMS final rule for the ESRD PPS.